I looked at KERX at the same time as I was looking at Rockwell about 4 months ago because everyone was saying that they were the competition. I think the two companies will exists in a similar space but the patient populations will be different with some minor overlap. Their drugs might even be symbiotic. But the main reason I didn't buy any KERX is because it's a molecule that was first patented in the 1930s. The question is will the FDA grant market exclusivity on a new indication for a drug that has been around so long. Maybe...maybe not but the judge and jury is the FDA and they won't rule for about 6 months. I think several hundred million might be a fair valuation of KERX at this juncture because of that risk. But $1B is way too high right now. I feel like the very high share price is fund managers driving the stock high and dumping it on retails. I think part of that dump was what you saw today. I don't say this with joy. It actually makes me angry because a lot of people lost a lot of money today to some very greedy fund managers. From my perspective this is not a competition between KERX investors and RMTI investors but the fund managers want to pit us against each other. Retails should work with each other, not against.